Loading…
Agenus Inc. is projected to rise to $3.45 by 2027, a +1% move from its current price of $3.41. AGEN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.25 | $3.41 | $3.58 | -0.04% |
| May 30 | $3.18 | $3.41 | $3.65 | -0.08% |
| May 31 | $3.14 | $3.41 | $3.70 | -0.12% |
| Jun 1 | $3.09 | $3.40 | $3.75 | -0.16% |
| Jun 2 | $3.06 | $3.40 | $3.79 | -0.20% |
| Jun 3 | $3.03 | $3.40 | $3.82 | -0.24% |
| Jun 4 | $3.00 | $3.40 | $3.86 | -0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.00 | $3.40 | $3.86 | -0.28% |
| Week 2 | $2.84 | $3.39 | $4.05 | -0.57% |
| Week 3 | $2.72 | $3.38 | $4.21 | -0.85% |
| Week 4 | $2.62 | $3.37 | $4.34 | -1.13% |
| Week 5 | $2.53 | $3.36 | $4.46 | -1.41% |
| Week 6 | $2.46 | $3.35 | $4.57 | -1.69% |
| Week 7 | $2.39 | $3.34 | $4.67 | -1.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Agenus Inc. is a clinical-stage biotechnology company that discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody, and a pipeline of antibody programs including AGEN1181, AGEN2373, AGEN1423, AGEN1571, and BMS-986442, among others. Agenus operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. The company was founded in 1994 and is headquartered in Lexington, Massachusetts; it has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme.
Agenus Inc. (AGEN) is currently priced at $3.41 with a market cap of $142M and is ranked 4010. This places the stock as a smaller-cap biotech with a focused immunotherapy portfolio and several clinical programs.
The near-term technical picture shows bearish sentiment, with RSI14 at 50 and the stock trading below its SMA50 ($3.77) and SMA200 ($3.83). The 30-day price range spans $2.49 to $4.67, illustrating notable near-term volatility.
A major floor 40.3% below — a decisive break under it would weaken the trend.
The nearest floor, 9.4% below — buyers have tended to step in here.
The nearest ceiling, 41.6% above — a clean break opens room to run.
A major ceiling 61.8% above — clearing it would confirm fresh momentum.
Key AGEN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AGEN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.23 | Buy | $3.29 | Buy |
| MA 10 | $3.30 | Buy | $3.34 | Buy |
| MA 20 | $3.55 | Sell | $3.49 | Sell |
| MA 50 | $3.77 | Sell | $3.62 | Sell |
| MA 100 | $3.52 | Sell | $3.66 | Sell |
| MA 200 | $3.83 | Sell | $3.87 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.31 | Neutral |
| Stoch RSI (14) | 87.27 | Sell |
| CCI (20) | -31.68 | Neutral |
| Williams %R (14) | -56.16 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -10.73 | Sell |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 43.84 | Neutral |
| TRIX (15) | -0.60 | Sell |
| Awesome (5,34) | -0.61 | Sell |
| Ultimate (7,14,28) | 39.31 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 3.24 | Buy |
| ADX (14) | 14.33 | Neutral |
| ATR (14) | 0.15 | Info |
The near-term outlook is bearish in sentiment. RSI14 sits at 50, indicating neutral momentum within the bearish trend context. The price remains below the 50-day and 200-day moving averages, with SMA50 at $3.77 and SMA200 at $3.83, suggesting difficulty advancing without renewed buying strength.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.77 | $3.41 | $4.90 | 0% | Neutral | |
| $2.53 | $3.45 | $5.06 | +1% | Neutral | |
| $2.61 | $3.74 | $5.81 | +10% | Neutral | |
| $3.03 | $4.54 | $7.36 | +33% | Bullish | |
| $3.81 | $5.94 | $9.99 | +74% | Bullish | |
| $3.84 | $6.21 | $10.78 | +82% | Bullish | |
| $3.72 | $6.23 | $11.12 | +83% | Bullish | |
| $3.99 | $6.92 | $12.66 | +103% | Bullish | |
| $3.40 | $6.10 | $11.42 | +79% | Bullish | |
| $3.31 | $6.13 | $11.73 | +80% | Bullish | |
| $4.39 | $9.48 | $19.81 | +178% | Bullish | |
| $9.14 | $20.32 | $46.73 | +496% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.77 | $3.41 | $4.06 | +0.00% |
| June 2026 | $2.87 | $3.43 | $4.23 | +0.58% |
| July 2026 | $2.71 | $3.29 | $4.15 | -4.19% |
| August 2026 | $2.77 | $3.39 | $4.36 | +3.31% |
| September 2026 | $2.93 | $3.63 | $4.73 | +6.90% |
| October 2026 | $2.87 | $3.59 | $4.74 | -1.09% |
| November 2026 | $2.77 | $3.49 | $4.65 | -2.78% |
| December 2026 | $2.86 | $3.63 | $4.90 | +4.15% |
Click any year to see its month-by-month AGEN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect AGEN to range from $2.77 to $4.90 through 2026. The $3.41 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The AGEN price prediction for 2027 points to an average of $3.45 (low $2.53, high $5.06) — a potential gain of +1% on today's $3.41. A consolidation phase looks the most probable path here.
In 2028, AGEN is projected to trade between $2.61 and $5.81, averaging $3.74 — a potential gain of +10% from today's $3.41. That is up +9% on the projected 2027 average. Price action looks broadly range-bound.
Agenus Inc.'s 2029 outlook centres on $4.54, within a $3.03 to $7.36 range. That is up +21% on the projected 2028 average. That marks a +33% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, AGEN could reach as high as $9.99, with a base case around $5.94 and support toward $3.81 — roughly +74% from $3.41. Momentum favours further upside here.
Expect AGEN to range from $3.84 to $10.78 through 2031. The $6.21 average target implies a +82% move from current prices. That is up +5% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The AGEN price prediction for 2032 points to an average of $6.23 (low $3.72, high $11.12) — a potential gain of +83% on today's $3.41. Momentum favours further upside here.
In 2033, AGEN is projected to trade between $3.99 and $12.66, averaging $6.92 — a potential gain of +103% from today's $3.41. That is up +11% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Agenus Inc.'s 2034 outlook centres on $6.10, within a $3.40 to $11.42 range. That is -12% versus the projected 2033 average. That marks a +79% change versus current levels. Momentum favours further upside here.
By 2035, AGEN could reach as high as $11.73, with a base case around $6.13 and support toward $3.31 — roughly +80% from $3.41. Buyers look set to stay in control over this stretch.
Expect AGEN to range from $4.39 to $19.81 through 2040. The $9.48 average target implies a +178% move from current prices. That is up +55% on the projected 2035 average. Momentum favours further upside here.
The AGEN price prediction for 2050 points to an average of $20.32 (low $9.14, high $46.73) — a potential gain of +496% on today's $3.41. Buyers look set to stay in control over this stretch.
Investing $1,000 in AGEN today (≈ 293.255132 AGEN) could be worth
$5,957.68
+$4,957.68 (+496%) by 2050 · US Dollar
Based on the average projected AGEN price of $20.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AGENwould be worth at today's price.
$1,000 invested in AGEN on May 27, 2025 (≈ 281.690145 AGEN) would be worth
$960.56
-$39.44 (-3.9%) today · 0.96× · US Dollar
Based on a AGEN entry price of $3.55 vs. today's $3.41.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.15 | $1,082.54 | +8.3% |
| 1 month ago | $4.09 | $833.74 | -16.6% |
| 3 months ago | $3.36 | $1,014.88 | +1.5% |
| 6 months ago | $4.56 | $747.81 | -25.2% |
| 1 year ago | $3.55 | $960.56 | -3.9% |
| All time (5.0y) ago | $82.83 | $41.17 | -95.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AGEN forecast.
Our base-case forecast reaches $6.80 around 2033.
Implied market cap at $6.80: $283.17M
The multi-year forecast shows a progression from neutral to bullish over time. For 2026, the expected average price is $3.41 with a max of $4.90 and a min of $2.77 (ROI 0, sentiment NEUTRAL). In 2027, the average is $3.45 with a max of $5.06 (ROI 1, NEUTRAL); 2028 average $3.74 (max $5.81, ROI 9.8, NEUTRAL).
The outlook turns bullish from 2029 onward, with 2029 average $4.54 and max $7.36 (ROI 33). By 2030 the average is $5.94 (max $9.99, ROI 74.2); 2031 average $6.21 (max $10.78, ROI 82.1); 2032 average $6.23 (max $11.12, ROI 82.7); and 2033 average $6.92 (max $12.66, ROI 102.9). The bullish trajectory continues with 2040 average $9.48 (max $19.81, ROI 178) and 2050 average $20.32 (max $46.73, ROI 495.8).
These figures imply meaningful upside over the long run, though they are estimates, not guarantees, and subject to market and development risks.
Tap a question to reveal the answer.
The forecast shows an average price of $5.94 in 2030 with a max of $9.99 (ROI 74.2), indicating a bullish path by that year.
The long-term forecast depicts a bullish path from 2029 onward, with rising averages and high-end price targets (e.g., 2030 avg $5.94, 2040 avg $9.48, 2050 avg $20.32 and 2050 max $46.73). However, the near-term view is bearish and these are estimates, not guarantees.
Yes—the forecast shows multiple years with max prices above $10, including 2031 max $10.78, 2032 max $11.12, and 2033 max $12.66.
The 30-day range is $2.49 to $4.67.
The current price is $3.41 and the market cap is $142M.
Agenus Inc. Community Discussion
0Share your Agenus Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.